Syngene International Q2 profit drops 52% to ₹32 crore
In short
Syngene International said Q2 FY27 net profit fell 52% to ₹32 crore. Revenue dropped 8.6% to ₹833 crore, and EBITDA margin slipped to 17.7% from 21.9%.
This matters because earnings weakened sharply even as the company added new contracts. The report does not say how much those deals will add to future sales or profit.
What the reporting says
Syngene International reported a 52% year-on-year fall in Q2 FY27 net profit to ₹32 crore, with revenue down 8.6% to ₹833 crore and EBITDA margin narrowing to 17.7%. The company also signed its first manufacturing agreement for the Bayview biologics facility and secured a clinical supplies contract for its Bengaluru site. The report does not quantify the effect of those contracts on future earnings.
Why it matters
Syngene International reported Q2 FY27 net profit of ₹32 crore, down 52% year on year, as revenue fell to ₹833 crore and EBITDA margin eased to 17.7%. The company also announced its first manufacturing agreement for the Bayview biologics facility and a clinical supplies contract for Bengaluru. The report links the profit decline to lower Zoetis revenue and forex hedge losses, but the size of those hits is not given.